FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Albers Jeffrey W.						2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [BPMC]									all applic Directo	tor		10% O	wner	
(Last) (First) (Middle) C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET						3. Date of Earliest Transaction (Month/Day/Year) 12/14/2020									Officer (give title below) CEO and Pres		l Pres	Other (specify below) sident		
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)					_ 4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - N	on-Deri	vative	Sec	urit	ies Ac	quire	d, Di	isposed o	of, or Be	eneficial	lly C	Owned	l				
Date			2. Transa Date (Month/D		Execu y/Year) if any						4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a		and 5) S B O		5. Amount of Securities Beneficially Owned Following Reported		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 12/14/20					2020	20		M ⁽¹⁾		5,000	A	\$8.8	.8		146,434		D			
Common Stock 12/14/20					2020	20		S ⁽¹⁾		5,000	D	\$119.18	.9.18(2)		141,434		D			
		7	able II								posed of converti			/ Ov	vned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title at Amount of Securitie Underlyin Derivativ (Instr. 3 a	of s ng e Security	Der Sec	Price of rivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares	ber						

Explanation of Responses:

\$8.8

Option

(Right to

1. Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

M⁽¹⁾

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$119.00 to \$119.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(3)

5.000

3. This option was granted on February 10, 2015 and is fully vested as of the date hereof.

12/14/2020

/s/ Christopher Frankenfield, Attorney-in-Fact

5,000

12/16/2020

17,170

D

** Signature of Reporting Person

Common

Stock

02/10/2025

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.